Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 26, 2025Scientific ReportsOpen Access

The effects and mechanisms of Xiaoyao San on nonalcoholic fatty liver disease rat based on transcriptomics and proteomics analysis

View Full Paper
Ask AI
Bookmark
Share

Key result

Xiaoyao San significantly ameliorated high-fat diet-induced hepatic steatosis and liver injury in NAFLD rats by regulating the cAMP/PKA-mediated PPARα, FOXO1, and NF-κB signaling pathways.

Why the study?

There is no approved pharmaceutical intervention for NAFLD, and while Xiaoyao San has shown therapeutic efficacy, its underlying mechanisms remain unclear.

Does Xiaoyao San improve nonalcoholic fatty liver disease in a high-fat diet-induced rat model?

Population

High-fat diet-induced NAFLD rat model

Comparison

Xiaoyao San vs untreated or control conditions

Design

Preclinical animal study with transcriptomics and proteomics analysis

Authors

YLYunxiao LiuSWShuanghu WangAYAyesha Younas

Discussion

Loading...

Member takes

Overview

Hypothesis-generating for Xiaoyao San in rat NAFLD; leaves open human translation pending clinical trials.

Structured PICO

Does Xiaoyao San improve nonalcoholic fatty liver disease in a high-fat diet-induced rat model?

P
Population
24 male Sprague-Dawley rats, 6-8 weeks old, were used to establish a high-fat diet-induced NAFLD model to evaluate the therapeutic mechanisms of Xiaoyao San over 4 weeks.
I
Intervention
Xiaoyao San (XYS) 19.27 g/kg/day by gavage for 4 weeks
C
Comparator
Equal volume of normal saline by gavage for 4 weeks (NAFLD control group)
O
Outcome
Changes in body weight, liver index, hepatic steatosis, serum biomarkers (liver function, lipids, inflammatory factors), and transcriptomic/proteomic profilessurrogate

Xiaoyao San improves nonalcoholic fatty liver disease in a rat model by regulating the cAMP/PKA-mediated PPARα, FOXO1, and NF-κB signaling pathways.

Limitations

  • Absence of a positive control group due to the lack of approved positive drug treatments for NAFLD and adherence to the 3R's principles of animal research.

Cite This Study

Liu et al. (2025) studied Nonalcoholic Fatty Liver Disease (NAFLD) (n=24). Xiaoyao San (XYS) vs. Normal saline was evaluated. Xiaoyao San significantly ameliorated high-fat diet-induced hepatic steatosis and liver injury in NAFLD rats by regulating the cAMP/PKA-mediated PPARα, FOXO1, and NF-κB signaling pathways.

synapsesocial.com/papers/6a885be82c11edba2ecf22cehttps://doi.org/10.1038/s41598-025-91890-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mechanism of Xiaoyao San in treating non-alcoholic fatty liver disease with liver depression and spleen deficiency: based on bioinformatics, metabolomics and in vivo experiments2023 · 8 citations
  2. 2Mechanism Study of Xiaoyao San against Nonalcoholic Steatohepatitis-Related Liver Fibrosis Based on a Combined Strategy of Transcriptome Analysis and Network Pharmacology2024 · 4 citations
  3. 3Revealing action mechanisms of Xiaoyaosan decoction for the treatment of nonalcoholic fatty liver in mice employing tandem mass tag quantitative proteomics2025
  4. 4Revealing action mechanisms of Xiaoyaosan decoction for the treatment of nonalcoholic fatty liver in mice employing tandem mass tag quantitative proteomics2025
  5. 5Xiezhuo Tiaozhi formula inhibits macrophage pyroptosis in the non-alcoholic fatty liver disease by targeting the SIRT1 pathway2024 · 8 citations